Trial Profile

CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Namodenoson (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Can-Fite BioPharma

Most Recent Events

02 Jun 2026 According to a Can-Fite BioPharma media release, results from this trial were presented at the 2026 American Society of Clinical Oncology (ASCO) meeting.
02 Jun 2026 Results presented in the Can-Fite BioPharma Media Release.
13 May 2026 Results presented in a Can-Fite BioPharma Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com